Complex Generics — The High-Barrier Pocket
Hard-to-make dosage forms with fewer competitors, higher margins and a formulation-technology moat. This is Rubicon's strategic core — each form is mapped on difficulty, regulation, economics and Rubicon's capability fit.
Explains the 'hard-to-copy' dosage forms — inhalers, patches, nasal sprays, depot injections — that are far more profitable than ordinary pills because few competitors can make them. This is Rubicon's strategic home turf.
Each card is one dosage-form family: what it is, why it's hard, the regulatory path, typical margins and a 0–10 'Rubicon fit' score at the bottom. Higher fit + lower competition = the most attractive opportunities.
- ER / modified-release
- — Pills engineered to release the drug slowly over hours, reducing dosing frequency.
- Transdermal
- — A skin patch that delivers drug through the skin over time.
- Bioequivalence (BE)
- — Proving a generic behaves the same in the body as the brand — harder for complex forms.
- Drug-device combo
- — A product where a device (e.g. an auto-injector or spray pump) is integral to the drug.
Extended / Modified Release
Drug released over time via matrix or coating systems to reduce dosing frequency.
Challenge: Reproducing the innovator release profile across the GI tract.
Transdermal Patch
Drug delivered through skin via an adhesive matrix/reservoir patch.
Challenge: Adhesion, permeation enhancers, residual drug, wear studies.
Nasal Spray
Drug delivered as a metered spray to nasal mucosa (local or systemic).
Challenge: Device equivalence, spray characterization, human factors.
Dry Powder Inhaler (DPI)
Micronized drug delivered to the lung via a breath-actuated device.
Challenge: Aerodynamic particle size, device, clinical equivalence.
Depot / Long-Acting Injectable
Sustained-release injectable (microspheres/suspension) dosed weekly-monthly.
Challenge: Particle engineering, release kinetics, sterility.
Ophthalmic
Sterile eye preparations — solutions, emulsions, suspensions.
Challenge: Sterility, Q1/Q2 formulation sameness, particle size.
Drug-Device Combination
Products where a device is integral to delivery (auto-injectors, sprays, patches).
Challenge: Device design, human factors, combined regulatory review.
Abuse-Deterrent / Controlled Substance
Formulations resistant to abuse and/or scheduled controlled substances.
Challenge: Abuse-deterrence characterization, DEA quota.